| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 142, 557-567, Copyright © 1993 by American Society for Investigative Pathology
REGULAR ARTICLES |
P Garin-Chesa, I Campbell, PE Saigo, JL Lewis Jr, LJ Old and WJ Rettig
Ludwig Institute for Cancer Research, New York Unit, New York.
The LK26 antigen is a cell surface glycoprotein (M(r)35,000 to 40,000) of normal placenta and gestational choriocarcinomas that shows highly restricted distribution in normal tissues, being expressed primarily in a subset of simple epithelia. In this study, immunohistochemical methods were used to examine LK26 expression in 78 ovarian tumors and > 400 tumors of other histological types. Ovarian carcinomas derived from coelomic epithelium showed the most consistent and strongest immunostaining for LK26, with 52 of 56 cases being LK26+. Ovarian tumors of sex cord, germ cell, and stromal origin were generally LK26-. LK26 was not found in normal fetal or adult ovary; however, it was present in the lining epithelia of some benign ovarian cysts. Mesotheliomas, which share a common mesothelial origin with LK26+ ovarian tumors, expressed no or only low levels of LK26. Other epithelial cancers expressed LK26 in subsets of cases and generally showed heterogeneous or weak immunostaining; this group of LK26+ tumors includes endometrial (10 of 11 cases tested), colorectal (six of 27), breast (11 of 53), lung (six of 18), and renal cell (nine of 18) carcinomas. Four of five brain metastases derived from epithelial cancers and three of 21 neuroendocrine carcinomas showed prominent LK26 immunoreactivity. Only rare neuroectodermal tumors (two of 70) and none of the sarcomas (none of 58) or lymphomas tested (none of 21) were LK26+. Tests with cultured cells showed that the LK26 proteins expressed in choriocarcinoma and ovarian cancer cells are biochemically similar, and transfection experiments identified LK26 as an adult-type, high-affinity folate-binding protein. The present study provides the first detailed specificity and sensitivity analysis for folate-binding protein/LK26 in human tumors and defines a role for folate-binding protein/LK26 in immunobiological studies of ovarian cancers and other LK26+ neoplasms.
This article has been cited by other articles:
 |
|
 |
|
  R. E. Fisher, B. A. Siegel, S. L. Edell, N. M. Oyesiku, D. E. Morgenstern, R. A. Messmann, and R. J. Amato Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor-Positive Solid Tumors J. Nucl. Med., June 1, 2008; 49(6): 899 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller, R. Schibli, E. P. Krenning, and M. de Jong Pemetrexed Improves Tumor Selectivity of 111In-DTPA-Folate in Mice with Folate Receptor-Positive Ovarian Cancer J. Nucl. Med., April 1, 2008; 49(4): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Iwakiri, M. Sonobe, S. Nagai, T. Hirata, H. Wada, and R. Miyahara Expression Status of Folate Receptor {alpha} Is Significantly Correlated with Prognosis in Non-Small-Cell Lung Cancers Ann. Surg. Oncol., March 1, 2008; 15(3): 889 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. He, H. Wang, L. C. Hartmann, J.-X. Cheng, and P. S. Low In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry PNAS, July 10, 2007; 104(28): 11760 - 11765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller, M. Bruhlmeier, P. A. Schubiger, and R. Schibli Effects of Antifolate Drugs on the Cellular Uptake of Radiofolates In Vitro and In Vivo J. Nucl. Med., December 1, 2006; 47(12): 2057 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sinha, G. J. Kim, S. Nie, and D. M. Shin Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther., August 1, 2006; 5(8): 1909 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bettio, M. Honer, C. Muller, M. Bruhlmeier, U. Muller, R. Schibli, V. Groehn, A. P. Schubiger, and S. M. Ametamey Synthesis and Preclinical Evaluation of a Folic Acid Derivative Labeled with 18F for PET Imaging of Folate Receptor-Positive Tumors J. Nucl. Med., July 1, 2006; 47(7): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rossin, D. Pan, K. Qi, J. L. Turner, X. Sun, K. L. Wooley, and M. J. Welch 64Cu-Labeled Folate-Conjugated Shell Cross-Linked Nanoparticles for Tumor Imaging and Radiotherapy: Synthesis, Radiolabeling, and Biologic Evaluation J. Nucl. Med., July 1, 2005; 46(7): 1210 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Jhaveri, A. S. Rait, K.-N. Chung, J. B. Trepel, and E. H. Chang Antisense oligonucleotides targeted to the human {alpha} folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment Mol. Cancer Ther., December 1, 2004; 3(12): 1505 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Theti and A. L. Jackman The Role of {alpha}-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs Clin. Cancer Res., February 1, 2004; 10(3): 1080 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Theti, V. Bavetsias, L. A. Skelton, J. Titley, D. Gibbs, G. Jansen, and A. L. Jackman Selective Delivery of CB300638, a Cyclopenta[g]quinazoline-based Thymidylate Synthase Inhibitor into Human Tumor Cell Lines Overexpressing the {alpha}-Isoform of the Folate Receptor Cancer Res., July 1, 2003; 63(13): 3612 - 3618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. M. Kelley, B. G. Rowan, and M. Ratnam Modulation of the Folate Receptor {alpha} Gene by the Estrogen Receptor: Mechanism and Implications in Tumor Targeting Cancer Res., June 1, 2003; 63(11): 2820 - 2828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Siegel, F. Dehdashti, D. G. Mutch, D. A. Podoloff, R. Wendt, G. P. Sutton, R. W. Burt, P. R. Ellis, C. J. Mathias, M. A. Green, et al. Evaluation of 111In-DTPA-Folate as a Receptor-Targeted Diagnostic Agent for Ovarian Cancer: Initial Clinical Results J. Nucl. Med., May 1, 2003; 44(5): 700 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Q. Pan, X. Zheng, G. Shi, H. Wang, M. Ratnam, and R. J. Lee Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta -targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid Blood, June 28, 2002; 100(2): 594 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Miotti, M Bagnoli, A Tomassetti, M. Colnaghi, and S Canevari Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1 J. Cell Sci., January 1, 2000; 113(2): 349 - 357. [Abstract] [PDF]
|
|
|
|
|
|
G. E. Peoples, B. W. Anderson, T. V. Lee, J. L. Murray, A. P. Kudelka, J. T. Wharton, and C. G. Ioannides Vaccine Implications of Folate Binding Protein, a Novel Cytotoxic T Lymphocyte-recognized Antigen System in Epithelial Cancers Clin. Cancer Res., December 1, 1999; 5(12): 4214 - 4223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wu, W. Gunning, and M. Ratnam Expression of Folate Receptor Type {{alpha}} in Relation to Cell Type, Malignancy, and Differentiation in Ovary, Uterus, and Cervix Cancer Epidemiol. Biomarkers Prev., September 1, 1999; 8(9): 775 - 782. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Reddy, L. S. Haneline, E. F. Srour, A. C. Antony, D. W. Clapp, and P. S. Low Expression and Functional Characterization of the beta -Isoform of the Folate Receptor on CD34+ Cells Blood, June 1, 1999; 93(11): 3940 - 3948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Lee and L. Huang Folate-targeted, Anionic Liposome-entrapped Polylysine-condensed DNA for Tumor Cell-specific Gene Transfer J. Biol. Chem., April 5, 1996; 271(14): 8481 - 8487. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
